Box 17

This series contains reprints of Gold’s articles. Also included within the series are drafts of some of Gold’s papers as well as an inventory of reprints compiled during an earlier processing of the collection.

This series contains reprints of Gold’s articles. Also included within the series are drafts of some of Gold’s papers as well as an inventory of reprints compiled during an earlier processing of the collection.

This series contains reprints of Gold’s articles. Also included within the series are drafts of some of Gold’s papers as well as an inventory of reprints compiled during an earlier processing of the collection.

This series contains reprints of Gold’s articles. Also included within the series are drafts of some of Gold’s papers as well as an inventory of reprints compiled during an earlier processing of the collection.

Subseries 11A consists of material relating to Gold’s health reports, vaccination records, passports, family finances, household memos, and World War II classification records.

Subseries 11A consists of material relating to Gold’s health reports, vaccination records, passports, family finances, household memos, and World War II classification records.

Series 13 consists of material relating to the Harry Gold Research Fund for Human Pharmacology, Inc. from the accrual to the Harry Gold, MD Papers. The series contains files relating to the organization’s incorporation in 1959 to its dissolution in 1971. It contains the organization’s founding documents, including the Certificate of Incorporation and Charter, as well as lists of members, Annual Reports, and the Certificate of Dissolution.

Series 14 is comprised of two folders containing material related to Gold’s testimony as an expert witness of medical issues for at least six legal proceedings, from the accrual to the Harry Gold, MD Papers processed in 2023. The bulk of the material consists of Gold’s testimonial notes and of memoranda relating to litigation regarding U. S. (Food and Drug Administration) v the Ames Company, Inc. (Decholin).

Series 14 is comprised of two folders containing material related to Gold’s testimony as an expert witness of medical issues for at least six legal proceedings, from the accrual to the Harry Gold, MD Papers processed in 2023. The bulk of the material consists of Gold’s testimonial notes and of memoranda relating to litigation regarding U. S. (Food and Drug Administration) v the Ames Company, Inc. (Decholin).